Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology

1 Mar 2007

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals the presence of DNA damage by catalyzing the addition of ADP-ribose units to DNA, histones, and various DNA repair enzymes and by facilitating DNA repair. PARP has been gaining increasing interest as a therapeutic target for many diseases and especially for cancer. Inhibition of PARP potentiates the activity of DNA-damaging agents, such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17332279
DOI: 10.1158/1078-0432.ccr-06-2260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologyPMID 17332279Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors as cancer therapySemantic proximity Read ↗

Development of PARP inhibitors in oncologySemantic proximity Read ↗

Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancersSemantic proximity Read ↗

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer TreatmentSemantic proximity Read ↗

Role of Biomarkers in the Development of PARP InhibitorsSemantic proximity Read ↗

PARP inhibitors in cancer therapy: an updateSemantic proximity Read ↗

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read ↗

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.Semantic proximity Read ↗

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in CancerSemantic proximity Read ↗

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.